{
  "pmcid": "10761379",
  "sha256": "fc3fba5e4568f02ccfe230fbea509f0b29ab857ff8e28c2d611fef16b14109db",
  "timestamp_utc": "2025-11-09T15:11:20.765274+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.840050607287452,
    "reading_ease": 44.01284412955465,
    "word_count": 208
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This study was a single-center phase 2 clinical trial."
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with a diagnosis of borderline resectable esophageal squamous cell carcinoma (BR-ESCC) because of the primary tumor or bulky lymph node that potentially invaded adjacent organs were eligible."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The treatment started with TPF chemotherapy followed by surgery if the cancer was resectable, or by concurrent chemoradiation if it was unresectable."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "This updated report presents the 3-year overall survival (OS) and progression-free survival (PFS) rates."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Surgery was performed for 27 patients (57.4%)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Surgery was performed for 27 patients (57.4%), and R0 resection was confirmed in 25 patients (53.2%)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The median OS for all the patients was 41.9 months (95% confidence interval [CI], 18.6–65.3 months), with a median PFS of 38.7 months (95% CI, 23.5–53.9 months)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration ClinicalTrials.gov identifer: NCT02976909 ."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}